INTRODUCTION
============

Preeclampsia (PE) is defined as a progressive, multisystemic disorder which characterized by triad of high-blood pressure to the extent of 140/90 mm Hg or more, oedema, as well as proteinuria, developing after 20 weeks of gestation \[[@B1]\]. And PE is one of the most common medical complications during pregnancy. The incidence of PE in pregnancies fluctuates ranging from 2% to 8% in the word \[[@B2],[@B3]\]. Furthermore, PE is also the leading cause of both perinatal and maternal morbidity and mortality in the world \[[@B4]\]. Complications of PE are the third leading cause of pregnancy-related deaths, just follows after haemorrhage and embolism among pregnancy-related cause of death \[[@B5]\]. PE is associated with increased risks of placental abruption, cerebrovascular and cardiovascular complications, acute renal failure, disseminated intravascular coagulation and maternal death \[[@B5]\]. Although it has been extensive studied, its specific pathophysiology and aetiology remain obscure \[[@B6],[@B7]\].

Copper is an important trace element which takes parts in structure of many enzymes like lysyl oxidase, cytochrome coxidase, tyrosinase, dopamine-β-hydroxylase, peptidylgly-cine alpha-amidating monooxygenase, monoamine oxidase, ceruloplasmin and copper--zinc superoxide dismutase (SOD) \[[@B8]\]. Many different studies have shown that there is an association between occurrence of PE and trace elements, however, the results are not consistent. To our knowledge, no meta-analysis has been conducted on the question. Given these reasons, we performed this meta-analysis to: (1) first assess the relationship between blood copper level and PE; (2) explore the potential heterogeneity among studies and (3) explore the potential publication bias.

MATERIALS AND METHODS
=====================

Literature search and selection
-------------------------------

We performed a systematic literature search from January 1990 to April 2016 using the databases of PubMed and Web of Science, using the following search terms: 'copper' and 'preeclampsia' to search the English related articles without restrictions. Moreover, we also reviewed the references of the included studies and review articles to identify additional studies which were not captured by our database searches.

Inclusion criteria
------------------

The inclusion criteria were as follows: (1) observational studies design; (2) the exposure of interest was copper level; (3) the outcome of interest was PE; (4) the blood sample was venous blood taken from cases and controls after the 20th week of pregnancy; (5) data of the plasma or serum copper levels are available in the results or can be obtained from the corresponding author; (6) data were presented as mean ± standard deviation (S.D.) (or data provided from which mean and S.D. could be calculated). Accordingly, we excluded reviews, letters, editorials and RCT studies.

All identified studies were carefully reviewed independently by two investigators to identify and determine whether an individual study was eligible for inclusion criteria in this meta-analysis. If the two reviewers could not reach a consensus about the eligibility of an article, it was resolved by disputing with a third investigator.

Data extraction
---------------

Two investigators independently performed the search, reviewing all identified studies and collecting data. The following data were extracted: the mean ± S.D. on plasma or serum copper levels, first authors' name, publication year, country where the study was performed, follow-up duration, mean age, criteria for PE diagnosis, sample size, fasting status before blood collection, determination method of plasma or serum copper levels and other information. If given the standard error mean (S.E.M.) of copper level in the study, the S.D. is calculated by the following formula: S.E.M.=S.D./![](bsr036e370tg1.jpg){#tg1}. Because the underlying units of measurement varied from study to study, all units were converted to ug/l.

Statistical analysis
--------------------

Pooled measure was calculated to assess the strength of association between plasma or serum copper level and PE. Because of the underlying units of measurement and experiment conditions varied from study to study, all statistical analyses were performed using standard mean difference (SMD) with 95% CI to assess the strength of association between copper level and PE \[[@B9]\]. The *I*^2^ was used to assess heterogeneity (*I*^2^ values of 0, 25, 50 and 75% represent no, low, moderate and high heterogeneity respectively) \[[@B10]\]. The random-effect model (REM) was adopted to calculate the combined results \[[@B11]\]. Meta-regression was performed to assess the potentially important covariates that might exert substantial impacts on between-study heterogeneity. The subgroup analyses (study type, geographic locations, sample type and fasting status) were also conducted to explore the between-study heterogeneity. A sensitivity analysis was performed with one study removed at a time to assess whether the results could have been affected markedly by a single study. Publication bias was investigated with visual inspection of the Egger test. All statistical analyses were performed with Stata 10.0 (Stata Corporation, College Station, TX, USA). All reported probabilities (*P* values) were two-sided with *P*\<0.05 considered statistically significant. The significance level for the tests of heterogeneity and publication bias is set at 0.1.

RESULTS
=======

Characteristics of studies
--------------------------

The detailed steps of our literature search are shown in [Figure 1](#F1){ref-type="fig"}. After the application of search strategy, we found that a total of 12 relevant articles \[[@B12]--[@B23]\] appeared to fulfil the inclusion criteria. All of the full texts, published between 1990 and 2016. All included studies are observational study, including case--control study and cross-sectional study. The pooled subjects included a total of 463 healthy pregnancy controls and 442 PE cases. The baseline characteristics of the study participants and design characteristics in the published articles are shown in [Table 1.](#T1){ref-type="table"}

![The flow diagram of screened, excluded and analysed publications](bsr036e370fig1){#F1}

###### Characteristics of all included studies

                                                                       Preeclampsia   Health control                                 
  ------------------------ ------------ ------------ ----------------- -------------- ---------------- ---- --------------- -------- -----------------------
  Açikgoz et al., 2006     Turkey       24.90±2.50   Case--control     16             2697±867         20   2810±884        Serum    No
  Ahsan et al., 2013       Bangladesh   26.05±5.41   Cross-sectional   44             1105±130         27   1040±130        Serum    No
  Atamer et al., 2005      Turkey       27.00±3.89   Cross-sectional   32             2612±472         28   1458±396        Serum    Overnight fast
  Bakacak et al., 2015     Turkey       29.20±3.56   Case--control     38             1995±263.58      40   1524.5±133.64   Serum    Overnight fast
  Borella et al., 1990     Italy        34-37        Case--control     24             3365.7±1245.4    35   2622.1±575.25   Plasma   Yes
  Farzin et al., 2012      Iran         27.43±3.91   Case--control     60             1182.8±169.2     60   1165.5±152.3    Serum    Yes
  Fenzl et al., 2013       Croatia      31.20        Case--control     30             2204.15±532.35   37   2082.6±476.45   Serum    Overnight fast
  Ilhan et al., 2002       Turkey       25.00        Case--control     21             1767.3±259.1     30   1581.5±278.6    Plasma   Overnight fast
  Kolusari et al., 2008    Turkey       27.91±5.21   Case--control     47             26.5±7.6         48   20.8±4.6        Serum    Overnight fast
  Rafeeinia et al., 2014   Iran         26.50±3.90   Case--control     50             2400±640         50   1300±340        Serum    Overnight fast
  Sarwar et al., 2013      Bangladesh   25.46±0.85   Case--control     50             1980±100         58   2580±60         Serum    8 h fasting condition
  Serdar et al., 2006      Turkey       25.00±2.30   Case--control     30             1880±480         30   1590±380        Serum    No

Plasma or serum copper level and PE
-----------------------------------

Eight of 12 included studies reported that copper levels were significantly higher in PE patients than controls, whereas 3 studies found no significant difference. However, Sarwar et al. \[[@B22]\] reported that copper levels were significantly lower in PE patients than controls. Of all included studies, the combined analysis results of 12 studies which showed all PE cases compared with healthy pregnancy between the copper level and PE was shown in forest plots ([Figure 2](#F2){ref-type="fig"}). When compared with healthy pregnancy controls, PE patients had a higher copper level. The pooled SMD from a REM was 0.69 ug/l (95% CI: 0.54--0.84, *I*^2^=96.7%; *P*\< 0.001).

![The forest plot of the association between copper level and PE risk](bsr036e370fig2){#F2}

Meta-regression and subgroup analyses
-------------------------------------

As seen in [Figure 2](#F2){ref-type="fig"}, strong evidence of heterogeneity among studies was demonstrated for plasma or serum copper and PE. However *P* values of univariate meta-regression analysis with the covariates of publication year, study type, fasting status of participants and geographic locations were 0.612, 0.241, 0.572 and 0.386 respectively. The results showed no covariates having a significant impact on between-study heterogeneity.

[Table 2](#T2){ref-type="table"} showed the results from subgroup analyses. Within all subgroups, the pooled SMD was consistently significant; indicating that copper level was higher in patients with PE than healthy pregnancy controls. The associations were significant both in the case-control studies \[SMD=0.61, 95% CI=0.45--0.77, *I*^2^=97.0%\] and cross-sectional studies \[SMD=1.20, 95% CI=0.80--1.60, *I*^2^=95.9%\]. The pooled SMD were significant in studies conducted among Asian populations \[SMD=0.73, 95% CI=0.57--0.90, *I*^2^=97.3%\] and European populations \[SMD=0.50, 95% CI=0.14--0.86, *I*^2^=58.9%\]. We also conducted a subgroup analysis stratified by fasting status of participants, the pooled SMD was 0.77 (95% CI=0.60--0.95, *I*^2^=97.6%) in the subgroup of fasting. The pooled SMD were 0.68 (95% CI=0.52--0.84, *I*^2^=97.3%) in the serum-based sample subgroup and 0.76 (95% CI=0.36--1.15, *I*^2^=0.0%) in the plasma-based sample subgroup.

###### Summary SMD for overall and subgroup results

  Subgroup                 Cases   Studies   SMD (95% CI)        *I*^2^ (%)   *P*~heterogeneity~
  ------------------------ ------- --------- ------------------- ------------ --------------------
  All studies              442     12        0.69 (0.54--0.84)   96.7         0.000
    Study type                                                                
      Case--control        366     10        0.61 (0.45--0.77)   97.0         0.000
      Cross-sectional      76      2         1.20 (0.80--1.60)   95.9         0.000
    Geographic locations                                                      
     Asia                  388     10        0.73 (0.57--0.90)   97.3         0.000
     Europe                54      2         0.50 (0.14--0.86)   58.9         0.000
  Sample type                                                                 
     Plasma                45      2         0.76 (0.36--1.15)   0.0          0.740
     Serum                 397     10        0.68 (0.52--0.84)   97.3         0.000
  Fasting status                                                              
     Yes                   352     9         0.77 (0.60--0.95)   97.6         0.000
     No                    90      3         0.42 (0.11--0.73)   45.4         0.160

Sensitivity analysis and publication bias
-----------------------------------------

As sensitivity analyses, we excluded one study at a time to assess the stability of the results. There was no significant change in the pooled SMD or 95% CI on excluding any of the studies. This means no individual study had excessive influence on the pooled effect between risk of plasma or serum copper and PE risk. The Egger test showed no evidence of significant publication bias for the analysis between plasma or serum copper level and PE for all included studies. The *P* value of Egger test was 0.268.

DISCUSSION
==========

In recent years, many studies had been performed to evaluate the relationship between blood copper level and PE based on populations. To our knowledge, our study is the first meta-analysis to discuss the association between plasma or serum copper level and PE. Our meta-analysis contained 12 studies, including 463 healthy pregnancy controls and 442 PE cases, identified that the plasma or serum copper level in PE patients was significantly higher than that in healthy pregnancy women.

PE is a multisystem and multifactorial disease that affects both mother and foetus by vascular dysfunction and by intrauterine growth restriction \[[@B24]\]. Although there has been implicated many pathophysiological factors in the aetiology of PE, its aetiology is still under investigation \[[@B25]\]. It is reported that excessive lipid peroxidation or oxidative stress is an important determinant of PE \[[@B24]\]. Oxidative stress contributes to maternal endothelial cell activation and enhanced apoptosis of trophoblasts and is believed to underlie the intense vasoconstriction and procoagulant state of PE \[[@B25]--[@B27]\]. Copper as an antioxidant trace metals, can alleviate oxidative stress by scavenging free radicals or function as essential substrates or cofactors for the adequate activation of antioxidant enzymes, such as SOD. In addition, Cu deficiency has a negative effect on Cu--Zn SOD enzyme system \[[@B28]\]. Cu--Zn SOD acts as antioxidant defence system. Subsequently impaired Cu--Zn SOD activity contributes to the oxidative damage in the body which may worsen several disease states \[[@B29]\].

Between-study heterogeneity is common in meta-analysis \[[@B30]\], and it is essential to explore the potential sources of between-study heterogeneity. An indeterminate number of characteristics that varied among the studies could be the sources, such as publication year, study type, fasting status of participants, geographic locations and other variation of the covariates in studies. Thus we used both meta-regression and sensitive analysis that aimed to explore the potential important causes of the between-study heterogeneity. Our meta-analysis did not find the covariates of publication year, study type, fasting status of participants and geographic locations as the important contributors to the between-study heterogeneity. When we conducted the subgroup analysis, the between-study heterogeneity was also persisted in some subgroups. The potential contributors to the conflicting results could be that: (1) the included studies with different blood sample handling methods and preservation methods; (2) the potential confounders adjusted in each study were diverse etc.

As a meta-analysis of relevant published studies, our study has several strengths. First, the large numbers of participants allow a much greater possibility of reaching reasonable conclusions and conducting subgroup analysis. Second, the literatures search and data extraction was conducted independently by two investigators; therefore, the random error introduced by inserting data into tables was avoided greatly. Third, we set a strict inclusion criterion to control the quality of including studies. Fourth, after conducting the subgroup analysis and sensitive analysis, the results showed consistent significant association with the one based on all studies, strongly identifying the association stable.

However, our study also has limitations. First, significant heterogeneity existed overall. To clarify the sources of heterogeneity, we conducted the subgroup and sensitivity analyses. However, residual confounding factors across studies remain as a cause for concern in this meta-analysis. Therefore, heterogeneity was still an inevitable problem that may affect the precision of overall results. Second, we found significant associations between copper levels with the risk of PE both in the Asian populations and European populations. However, only two studies came from Europe, so, more studies originating in Europe and other countries are required to investigate the association between copper levels and PE risk. Due to this limitation, the results are applicable to the Asia, but cannot be extended to populations elsewhere. Finally, although we only included the article written in English and did not search grey literature, the Egger test showed no evidence of significant publication bias for the analysis between plasma or serum copper level and PE for all included studies. The *P* value of Egger test was 0.268.

In summary, results from this meta-analysis indicate that plasma or serum copper level in PE patients was significantly higher than that in healthy pregnancy women.
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